TRINETRA › Sectors › Healthcare
Sanofi India Limited (SANOFI) — share price, P/E and fundamentals
Sanofi India Limited (NSE: SANOFI) closed at ₹3,204.10 on 30 Oct 2026, -31.5% over one year, against a 52-week range of ₹2,760.70 – ₹4,898.00.
In the quarter ended 30 Sept 2026 (standalone, filed 29 Oct 2026) it reported revenue of ₹492 cr and net profit of ₹117 cr, a 23.7% net margin; revenue grew 3.4% and profit grew 54.2% year on year.
On four consecutive filed quarters its trailing P/E is 20.2; since 25 Feb 2026 its own P/E has ranged from 19.8 to 29.1 (median 23.9), and today's reading is higher than 2% of those 164 trading days.
From the balance sheet dated 30 Jun 2026: return on equity 56.5%, ROCE 75.4%, debt-to-equity 0.00, Piotroski F-score 6 of 9.
Against 66 Healthcare peers on NSE: Net margin higher than 86% of 64 sector peers; PBT margin higher than 88% of 64 sector peers; ROE higher than 98% of 64 sector peers.
Key figures
| Last close | ₹3,204.10 (30 Oct 2026) |
|---|---|
| Change 1 month / 6 months / 1 year | +2.3% / -6.5% / -31.5% |
| 52-week low – high | ₹2,760.70 – ₹4,898.00 |
| Market capitalisation | ₹7,369 cr |
| Trailing P/E | 20.2 |
| Price / book | 8.92 |
| EV / EBITDA | 13.3 |
| Earnings yield | 5.0% |
| TTM EPS | ₹158.48 |
| TTM net profit | ₹365 cr |
| Quarter revenue | ₹492 cr |
| Quarter net profit | ₹117 cr |
| Net margin | 23.7% |
| Revenue growth (YoY) | +3.4% |
| Profit growth (YoY) | +54.2% |
| Return on equity | 56.5% |
| ROCE | 75.4% |
| Debt / equity | 0.00 |
| Current ratio | 1.90 |
| Free cash flow | ₹201 cr |
| Piotroski F-score | 6 / 9 |
| Average daily turnover (50 days) | ₹4.6 cr |
Against Healthcare peers
| Metric | SANOFI | Peer median | Percentile |
|---|---|---|---|
| Net margin | 23.73 | 12.89 | 86 |
| PBT margin | 32.07 | 17.68 | 88 |
| ROE | 56.51 | 13.87 | 98 |
| ROCE | 75.43 | 17.26 | 98 |
| Debt / equity | 0.00 | 0.11 | 12 |
| FCF margin | 14.33 | -0.87 | 67 |
| Cash conversion | 0.70 | 1.25 | 15 |
| Trailing P/E | 20.22 | 43.26 | 8 |
Questions
What is the P/E ratio of Sanofi India Limited?
Sanofi India Limited's trailing P/E is 20.2, using the close of 30 Oct 2026 and earnings over the four filed quarters to 30 Sept 2026. Since 25 Feb 2026 its P/E has ranged 19.8–29.1.
What were Sanofi India Limited's latest quarterly results?
For the quarter ended 30 Sept 2026, Sanofi India Limited reported revenue of ₹492 cr and net profit of ₹117 cr (standalone), filed with the exchange on 29 Oct 2026.
What is Sanofi India Limited's ROE?
Return on equity is 56.5% based on the balance sheet dated 30 Jun 2026.
Does Sanofi India Limited have debt?
Debt-to-equity is 0.00 on the balance sheet dated 30 Jun 2026.
What is SANOFI's 52-week high and low?
Over the last 52 weeks to 30 Oct 2026, SANOFI traded between ₹2,760.70 and ₹4,898.00.
Other Healthcare stocks
- Sun Pharmaceutical Industries Limited (SUNPHARMA)
- Divi's Laboratories Limited (DIVISLAB)
- Torrent Pharmaceuticals Limited (TORNTPHARM)
- Laurus Labs Limited (LAURUSLABS)
- Zydus Lifesciences Limited (ZYDUSLIFE)
- Apollo Hospitals Enterprise Limited (APOLLOHOSP)
- Dr. Reddy's Laboratories Limited (DRREDDY)
- Cipla Limited (CIPLA)
- Mankind Pharma Limited (MANKIND)
- Aurobindo Pharma Limited (AUROPHARMA)
- Lupin Limited (LUPIN)
- Max Healthcare Institute Limited (MAXHEALTH)
Source: standalone SEBI Integrated Filing for the quarter ended 30 Sept 2026 and NSE daily closes. Open the interactive terminal view for charts and the full statements.
TRINETRA is a research and education tool. Nothing on this site is investment advice or a recommendation to buy or sell any security. Markets carry risk; do your own research and consult a SEBI-registered adviser before investing. Figures are as filed with NSE/SEBI and as of the dates shown; they are not live prices.